Previous 10 | Next 10 |
home / stock / rkv:cc / rkv:cc news
VANCOUVER, British Columbia, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company focused on the development of novel DNA-damage response (DDR) inhibitors to address high unmet medical needs in the treatment of cancer...
--News Direct-- Rakovina Therapeutics Executive Chairman Jeffery Bacha joined Steve Darling from Proactive to discuss the company's corporate highlights as part of its second-quarter financial report. Bacha highlighted several significant developments for the company during this perio...
VANCOUVER, British Columbia, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients through development of novel DNA-damage response inhibitor therapeutics, announced f...
VANCOUVER, British Columbia, June 28, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “ Company ”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, is pleased to announce the results of...
VANCOUVER, British Columbia, May 31, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients through development of novel DNA-damage response inhibitor therapeutics, announced fi...
VANCOUVER, British Columbia, May 29, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“ Rakovina ” or the “ Company ”) ( TSX-V: RKV ) is pleased to announce that it has closed its previously announced non-brokered private placement (the “ Offer...
VANCOUVER, British Columbia, May 01, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, announced the financial results for its fourt...
--News Direct-- Rakovina Therapeutics chief scientific officer Mads Daugaard joined Steve Darling from Proactive with news that the company has shared new data at the American Association of Cancer Research meeting in Orlando, Florida. Daugaard tells Proactive the data describes the p...
VANCOUVER, British Columbia, April 20, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (the “ Company ”) (TSXV:RKV) today announced the presentation of new data describing the progress of the Company’s kt-3000 drug development program at the American Association of Ca...
VANCOUVER, British Columbia, March 30, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (the “ Company ”) (TSXV:RKV) today announced the engagement of Red Cloud Securities (“ Red Cloud ”) and Proactive Investors North America Inc. (“ Proactive ...
News, Short Squeeze, Breakout and More Instantly...
Rakovina Therapeutics Inc. Company Name:
RKV:CC Stock Symbol:
TSXVC Market:
VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or “Rakovina Therapeutics”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies i...
VANCOUVER, British Columbia, April 26, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its four...
VANCOUVER, British Columbia, April 09, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), (“Rakovina” or the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients through the development of novel DNA-damage response ...